HK1184854A1 - 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物 - Google Patents
貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物Info
- Publication number
- HK1184854A1 HK1184854A1 HK13112206.0A HK13112206A HK1184854A1 HK 1184854 A1 HK1184854 A1 HK 1184854A1 HK 13112206 A HK13112206 A HK 13112206A HK 1184854 A1 HK1184854 A1 HK 1184854A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- breast cancer
- blood plasma
- combination therapies
- plasma biomarkers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170008 | 2010-07-19 | ||
PCT/EP2011/062232 WO2012010552A1 (en) | 2010-07-19 | 2011-07-18 | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1184854A1 true HK1184854A1 (zh) | 2014-01-30 |
Family
ID=44545675
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13112206.0A HK1184854A1 (zh) | 2010-07-19 | 2013-10-30 | 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物 |
HK16105145.5A HK1217093A1 (zh) | 2010-07-19 | 2013-10-30 | 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16105145.5A HK1217093A1 (zh) | 2010-07-19 | 2013-10-30 | 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20130121999A1 (zh) |
EP (2) | EP2596363B1 (zh) |
JP (1) | JP6055764B2 (zh) |
KR (1) | KR20130091750A (zh) |
CN (2) | CN103109188B (zh) |
AU (1) | AU2011281706A1 (zh) |
BR (1) | BR112013001423A2 (zh) |
CA (1) | CA2804350A1 (zh) |
ES (1) | ES2619590T3 (zh) |
HK (2) | HK1184854A1 (zh) |
MX (1) | MX343801B (zh) |
NZ (1) | NZ603780A (zh) |
RU (1) | RU2013106938A (zh) |
SG (1) | SG187013A1 (zh) |
WO (1) | WO2012010552A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2558931C2 (ru) * | 2010-01-12 | 2015-08-10 | Нестек С.А. | Способы предсказания ответа трижды негативного рака молочной железы на терапию |
JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
AR089067A1 (es) * | 2011-12-05 | 2014-07-30 | Hoffmann La Roche | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama |
US9116159B2 (en) | 2012-05-22 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | VEGF-A121 assay |
KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
WO2016094273A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
BR112017017428A2 (pt) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | ?método para supressão do amargor de derivado de quinolina? |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
KR20190080825A (ko) | 2016-03-21 | 2019-07-08 | 다나-파버 캔서 인스티튜트 인크. | T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도 |
US9950070B2 (en) | 2016-08-16 | 2018-04-24 | Korea University Research And Business Foundation | HER2 aptamer-anticancer drug complex for cancer cell chemotherapy |
KR102247908B1 (ko) | 2020-10-08 | 2021-05-06 | 주식회사 엠디엡투스 | Her2 압타머-항암 약물 복합체 및 이의 용도 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19806989A1 (de) | 1998-02-19 | 1999-08-26 | Roche Diagnostics Gmbh | Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays |
US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
EP1575416B1 (en) * | 2002-07-19 | 2013-10-02 | Beth Israel Deaconess Medical Center | Methods of diagnosing pre-eclampsia |
DE102004029909A1 (de) | 2004-06-21 | 2006-01-19 | Roche Diagnostics Gmbh | Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern |
US20090010887A1 (en) * | 2004-10-06 | 2009-01-08 | Ben-Sasson Shmuel A | Method and composition for enhancing anti-angiogenic therapy |
WO2007059094A2 (en) * | 2005-11-14 | 2007-05-24 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
US9675578B2 (en) * | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
WO2008088854A2 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
EP2125016A2 (en) * | 2007-02-01 | 2009-12-02 | Genetech, Inc. | Combination therapy with angiogenesis inhibitors |
EP2065399A1 (en) * | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy |
CN102016579B (zh) * | 2007-11-30 | 2015-04-08 | 健泰科生物技术公司 | Vegf多态性和抗血管发生疗法 |
US20100004306A1 (en) * | 2008-06-18 | 2010-01-07 | Abbott Laboratories | PIGF-1 Assay and kits and components thereof |
KR101596539B1 (ko) * | 2008-12-23 | 2016-02-22 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
-
2011
- 2011-07-18 CN CN201180044840.2A patent/CN103109188B/zh not_active Expired - Fee Related
- 2011-07-18 KR KR1020137004172A patent/KR20130091750A/ko not_active Application Discontinuation
- 2011-07-18 EP EP11746191.3A patent/EP2596363B1/en active Active
- 2011-07-18 ES ES11746191.3T patent/ES2619590T3/es active Active
- 2011-07-18 CN CN201510684543.4A patent/CN105327347A/zh active Pending
- 2011-07-18 MX MX2013000673A patent/MX343801B/es active IP Right Grant
- 2011-07-18 BR BR112013001423A patent/BR112013001423A2/pt not_active IP Right Cessation
- 2011-07-18 NZ NZ60378011A patent/NZ603780A/en not_active IP Right Cessation
- 2011-07-18 CA CA2804350A patent/CA2804350A1/en not_active Abandoned
- 2011-07-18 WO PCT/EP2011/062232 patent/WO2012010552A1/en active Application Filing
- 2011-07-18 EP EP16184951.8A patent/EP3156800A1/en not_active Withdrawn
- 2011-07-18 JP JP2013520106A patent/JP6055764B2/ja not_active Expired - Fee Related
- 2011-07-18 AU AU2011281706A patent/AU2011281706A1/en not_active Abandoned
- 2011-07-18 RU RU2013106938/15A patent/RU2013106938A/ru not_active Application Discontinuation
- 2011-07-18 SG SG2013001946A patent/SG187013A1/en unknown
-
2012
- 2012-12-27 US US13/728,411 patent/US20130121999A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/801,914 patent/US20130183302A1/en not_active Abandoned
- 2013-03-13 US US13/801,923 patent/US20130183303A1/en not_active Abandoned
- 2013-10-30 HK HK13112206.0A patent/HK1184854A1/zh not_active IP Right Cessation
- 2013-10-30 HK HK16105145.5A patent/HK1217093A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN103109188B (zh) | 2015-11-25 |
EP2596363A1 (en) | 2013-05-29 |
US20130183303A1 (en) | 2013-07-18 |
NZ603780A (en) | 2015-04-24 |
US20130121999A1 (en) | 2013-05-16 |
AU2011281706A1 (en) | 2013-01-10 |
BR112013001423A2 (pt) | 2016-05-24 |
EP3156800A1 (en) | 2017-04-19 |
MX2013000673A (es) | 2013-02-27 |
JP6055764B2 (ja) | 2016-12-27 |
CA2804350A1 (en) | 2012-01-26 |
CN103109188A (zh) | 2013-05-15 |
CN105327347A (zh) | 2016-02-17 |
HK1217093A1 (zh) | 2016-12-23 |
EP2596363B1 (en) | 2017-01-18 |
MX343801B (es) | 2016-11-23 |
WO2012010552A1 (en) | 2012-01-26 |
US20130183302A1 (en) | 2013-07-18 |
ES2619590T3 (es) | 2017-06-26 |
KR20130091750A (ko) | 2013-08-19 |
JP2013534308A (ja) | 2013-09-02 |
SG187013A1 (en) | 2013-02-28 |
RU2013106938A (ru) | 2014-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1184854A1 (zh) | 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物 | |
HK1254859A1 (zh) | 治療乳腺癌的方法 | |
HK1201413A1 (zh) | 乳癌的治療 | |
ZA201403602B (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
IL228738A0 (en) | Antibodies for cancer treatment | |
EP2542081A4 (en) | COMPOSITIONS FOR CANCER TREATMENT | |
HK1202253A1 (zh) | 癌症的聯合治療 | |
ZA201300218B (en) | Treatment of blood cancer | |
HK1181459A1 (zh) | 貝伐單抗組合療法用於治療胰腺癌的血漿生物標誌物 | |
EP2788378A4 (en) | ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER | |
HRP20181757T1 (hr) | Kombinirana terapija za liječenje raka dojke | |
EP2608671A4 (en) | COMPOUNDS USED IN THE TREATMENT OF CANCER | |
IL275636A (en) | Medical combination for cancer treatment | |
HK1202334A1 (zh) | 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物 | |
WO2012106461A9 (en) | Combination therapy for treatment of cancer | |
GB201121791D0 (en) | Combination treatment of cancer | |
GB201017354D0 (en) | Treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200721 |